Dr. Cavalier is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
50 Binney St
Cambridge, MA 02142Phone+1 857-202-7146- Is this information wrong?
Summary
- Board certified neurologist with specialty in MS. Practiced for 25 years. For past 8 years have worked in pharma in the area of MS. Currently, head of global MS scientific communications for Sanofi Genzyme.
Education & Training
Cleveland Clinic FoundationResidency, Neurology, 1978 - 1981
Tulane University School of MedicineClass of 1977
Certifications & Licensure
LA State Medical License 1977 - 2013- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 6 citationsEffects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and ext...Till Sprenger, Ludwig Kappos, Maria Pia Sormani, Aaron E Miller, Elizabeth M Poole, Steven Cavalier, Jens Wuerfel> ;Multiple Sclerosis. 2022 Oct 1
- 10 citationsProportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.Dana Horakova, Aaron Boster, Antonio Bertolotto, Mark S. Freedman, Isabel Firmino, Steven J. Cavalier, Alan Jacobs, Karthinathan Thangavelu, Nadia Daizadeh, Elizabeth ...> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2020 Dec 18
- 7 citationsSlowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MSRobert Zivadinov, Michael G. Dwyer, Ellen Carl, Elizabeth M. Poole, Steve Cavalier, Paraskevi Briassouli, Niels Bergsland> ;Therapeutic Advances in Neurological Disorders. 2020 Nov 11
- Join now to see all
Journal Articles
- Teriflunomide in the TOPIC Study: Effect on Cortical Gray Matter AtrophyZivadinov R, Dwyer MG, Carl E, Thangavelu K, Cavalier S, Bergsland N (Order TBC), The Lancet Neurology, 2/26/2019
- Correlation Between Brain Volume Loss and Long-term Disability Worsening in Patients With MS: SIENA Analysis of TEMSO MRI DataSprenger T, Kappos L, Radue EW, Gaetano L, Mueller-Lenke N, Wuerfel J, Thangavelu K, Cavalier S, Multiple Sclerosis Journal, 1/9/2019
- Rate of conversion from relapsing-remitting MS to secondary progressive MS in patients treated with alemtuzumab: 6-year follow-up of CARE-MS I and IIHorakova D, Boster A, Bertolotto A, Freedman MS, Firmino I, Cavalier SJ, Thangavelu K, Margolin DH, Ziemssen T; on behalf of the CARE-MS I, CARE-MS II, and CAMMS03409 ..., JAMA Neurology, 1/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
